Clinical studies that showed even modest metabolic effects used 900 to 1,500 mg taken orally
Elevated fasting insulin, visceral adiposity, non-alcoholic fatty liver disease, and chronic systemic inflammation are not merely cardiovascular or endocrine risk factors they represent a hostile cellular environment in which neoplastic transformation is more likely to occur, progress, and evade immune surveillance
Demand for Ozempic and its kin is tremendous, but many people cant access these drugs because of cost and supply issues
Despite its recent rise, many claims related to berberines role in GLP-1 production have not been clinically validated
doi: 10.1371/journal.pgph.0005516, 72 JohnsonP
Some studies show that adding a GLP-1 agonist to basal insulin results in better blood sugar control with neutral weight effects, or even mild weight loss, compared to intensifying insulin alone